Remove Biosimilars Remove Government Remove Therapies
article thumbnail

COMMERCIALIZATION AND LICENSE AGREEMENT FOR PROPOSED BIOSIMILAR CURRENTLY IN PHASE 3 WITH THE POTENTIAL TO TREAT MODERATE TO SEVERE RHEUMATOID ARTHRITIS

The Pharma Data

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability.

article thumbnail

Informa Connect's Hub and Specialty Pharmacy Models West

Drug Channels

President and CEO, National Pharmaceutical Council Julie Ritchie Wagner, Senior Assistant General Counsel, Head of Global Ethics, Compliance, and Enforcement Legal Policy, PhRMA Joel White, Founder and President, Horizon Government Affairs Charlene Keller Fullmer, Assistant U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Prescribing Red Flags and Suspicious Controlled Substance Orders: Current Cautionary Tales

FDA Law Blog: Biosimilars

The government asserted additional allegations that are outside our scope. Prescribing Red Flags The government alleged that from at least 2017 to April 2021 Defendants knowingly filled controlled substance prescriptions “that raised obvious ’red flags’ of potential abuse or diversion.” Zarzamora Press Release. Complaint ¶ 55.

Pharmacy 139
article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

Shorter exclusivity periods, driven by patent challenges and the introduction of generic or biosimilar competitors, significantly contribute to declining ROI. When a drug loses patent protection, generic or biosimilar versions can enter the market, leading to a rapid decline in sales for the original brand-name drug.

article thumbnail

Navigating FDA User Fee Updates for Fiscal Year 2023

thought leadership

Government begins its fiscal year on October 1, it signifies the annual revisions in FDA User Fees, which have an impact on applications and facilities associated with Prescription Drugs (including small molecules, vaccines, cell and gene therapy products, biologics, etc.), Generic Drugs, Biosimilars, and Medical Devices.

FDA 45
article thumbnail

Article FDA Thank You Explainer: What a government shutdown would mean for the FDA (Updated)

Agency IQ

Explainer: What a government shutdown would mean for the FDA (Updated) With Congress again debating the passage of appropriations legislation, the FDA is facing a potential shutdown of operations as of Midnight on March 1. What is a government shut down? If none of the 12 bills are completed, then all government operations shut down.

article thumbnail

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

The Pharma Data

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. government, we could become subject to significant sanctions.